Compare Viatris Inc (VTRS) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Zillow Group Inc Class A — how do they compare? Viatris Inc trades at $16.45 (market cap $18.95B), while Zillow Group Inc Class A trades at $32.92 (market cap $7.26B). The key difference: Viatris Inc is far larger — about 2.6× Zillow Group Inc Class A's market cap, and Viatris Inc pays a 2.91% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals.
| VTRS | ZG | |
|---|---|---|
Market Cap | $18.95B | $7.26B |
Sector | Health | Media |
52-Week High | $17.86 | $86.76 |
52-Week Low | $9.49 | $29.14 |
Enterprise Value | $31.07B | $7.14B |
Dividend Yield | 2.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Zillow Group (ZG) trades at $33.03, down 6.48% over 24 hours, reflecting bearish technical signals amid a challenging housing market. The stock shows mixed fundamentals with a high P/E ratio of 143.57 but improving revenue growth to $2.58B in 2025 and a return to net profitability. Recent news highlights Zillow's shift to an integrated transaction platform and a settled FTC lawsuit, while analyst consensus remains cautiously optimistic with a $47.56 price target.
The outlook balances growth potential from Zillow's monetization strategy against near-term headwinds like elevated interest rates dampening home sales. Risks include execution challenges in the business model transition and competitive pressures, but institutional buying and earnings beats suggest underlying strength. Investors should weigh the high valuation against improving cash flow and market positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
